Cargando…

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis

Objective. The aim of this study was to identify serum markers that are modulated by an investigational anti-IFN-α mAb, sifalimumab, in adult DM or PM patients. Methods. In a phase 1b clinical trial, sera were collected from a total of 48 DM or PM adult patients receiving either placebo for 3 months...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiang, Higgs, Brandon W., Rebelatto, Marlon, Zhu, Wei, Greth, Warren, Yao, Yihong, Roskos, Lorin K., White, Wendy I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970566/ https://www.ncbi.nlm.nih.gov/pubmed/24357810 http://dx.doi.org/10.1093/rheumatology/ket413

Ejemplares similares

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
por: Higgs, Brandon W, et al.
Publicado: (2014)

Nutrition and Polymyositis and Dermatomyositis
por: Loell, Ingela, et al.
Publicado: (2008)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

Viral Etiology of Polymyositis/Dermatomyositis
por: DENMAN, A.M.
Publicado: (1988)

Subcutaneous Edema in Polymyositis and Dermatomyositis
por: Yoshimi, Ryusuke, et al.
Publicado: (2023)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Polymyositis and dermatomyositis: Disease spectrum and classification
por: Raychaudhuri, Siba P, et al.
Publicado: (2012)

Polymyositis and dermatomyositis – challenges in diagnosis and management
por: Yang, Shu-Han, et al.
Publicado: (2019)

Dermatomyositis and polymyositis in total hip arthroplasty
por: Rosas, Samuel, et al.
Publicado: (2021)

Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
por: Wong, David, et al.
Publicado: (2012)

Polymyositis and dermatomyositis as a risk of developing cancer
por: Jakubaszek, Michał, et al.
Publicado: (2015)

Cardiac involvement in polymyositis and dermatomyositis: diagnostic approaches
por: Trybuch, Agnieszka, et al.
Publicado: (2023)

Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
por: Enomoto, Yasunori, et al.
Publicado: (2017)

Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis
por: Hirai, Takuya, et al.
Publicado: (2018)

Potential role of autophagy in T-cell survival in polymyositis and dermatomyositis
por: Shu, Xiaoming, et al.
Publicado: (2017)

Hyaluronic acid in dermatomyositis and polymyositis: relationship with disease and cutaneous lesions
por: Silva, Marilda Guimarães, et al.
Publicado: (2018)

STROBE: The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis
por: Chai, Ke-Xia, et al.
Publicado: (2018)

Identification of hub biomarkers and immune cell infiltration in polymyositis and dermatomyositis
por: Chen, Si, et al.
Publicado: (2022)

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
por: Oddis, Chester V., et al.
Publicado: (2022)

New Onset of Dermatomyositis/Polymyositis during Anti-TNF-α Therapies: A Systematic Literature Review
por: Brunasso, Alexandra Maria Giovanna, et al.
Publicado: (2014)

Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan
por: Chen, Yi-Ju, et al.
Publicado: (2010)

Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis
por: Kim, Geun-Tae, et al.
Publicado: (2009)

The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease
por: Sugiyama, Yumiko, et al.
Publicado: (2018)

Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis
por: Liu, Tao, et al.
Publicado: (2017)

Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
por: Nissan, Ella, et al.
Publicado: (2021)

Supervised Physical Therapy and Polymyositis/Dermatomyositis—A Systematic Review of the Literature
por: Corrado, Bruno, et al.
Publicado: (2020)

Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022)

Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis
por: Palmucci, Stefano, et al.
Publicado: (2022)

Serum uric acid is independently associated with hypertension in patients with polymyositis and dermatomyositis
por: liu, mei, et al.
Publicado: (2023)

Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity
por: Suzuki, Fumihito, et al.
Publicado: (2012)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

HMGB1, a new proinflammatory molecule of interest in polymyositis and dermatomyositis patients
por: Grundtman, C, et al.
Publicado: (2003)

Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis
por: Shimojima, Yasuhiro, et al.
Publicado: (2012)

Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis
por: da Cunha, Gilmara Franco, et al.
Publicado: (2013)

Thrombotic Microangiopathy with Polymyositis/Dermatomyositis: Three Case Reports and a Literature Review
por: Yamada, Saeko, et al.
Publicado: (2018)

Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis
por: Li, Yanqing, et al.
Publicado: (2018)

Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis
por: Temmoku, Jumpei, et al.
Publicado: (2019)

Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers
por: Song, Jaeseung, et al.
Publicado: (2019)

Dermatomyositis and/or polymyositis as a paraneoplastic manifestation of ovarian cancer: a systematic review
por: Psomiadou, Victoria, et al.
Publicado: (2021)

Clinical Features of Anti-Synthetase Syndrome Associated with Prognosis in Patients with Dermatomyositis and Polymyositis
por: Ahn, Sung Soo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5rpud33517ugrlhhbci2fdfblf